HomeAI · summaries
Storia in 2 fonti
Wegovy, Ozempic regain weight as Indian generics fall behind
Novo Nordisk's weight-loss drugs are regaining market share from Indian generics. Innovator brands show steady month-on-month sales growth, unlike generics. Eli Lilly's tirzepatide brands also experienced sales growth in the recent period. Doctors prefer innovator semaglutide due to similar pricing and pioneering status. The crowded generic market is causing brands to lose their individual market share.
Confronto fonti
2 prospettive sulla stessa storiaTimeline cronologica
- ·
thehindubusinessline.com
Rush for GLP-1 weight-loss and diabetes drugs plateaus, says industry tracker
The GLP-1 weight-loss and diabetes drug market stabilizes as generics gain traction, with innovators maintaining steady sales, reports Pharmatrack.
- ·
economictimes.indiatimes.com
Wegovy, Ozempic regain weight as Indian generics fall behind
Novo Nordisk's weight-loss drugs are regaining market share from Indian generics. Innovator brands show steady month-on-month sales growth, unlike generics. Eli Lilly's…
